Papillomavirus infection. How to avoid relaps?
https://doi.org/10.21518/2079-701X-2018-6-142-144
Abstract
The paper presents data on the prevalence of PVI, the recurrence rate of this infection. It discusses various therapy protocols of the disease including the use of destructive methods in the treatment and combination of the above methods with immunomodulating therapy. The own observation data are provided.
About the Authors
O. O. Melnichenko
Moscow Scientific and Practical Center of Dermatology, Venereology and Cosmetology of Moscow City Health Department
Russian Federation
Russian Federation
O. R. Babaev
Moscow Scientific and Practical Center of Dermatology, Venereology and Cosmetology of Moscow City Health Department
Russian Federation
PhD in medicine
Russian Federation
PhD in medicine
V. V. Shakhzadov
Moscow Scientific and Practical Center of Dermatology, Venereology and Cosmetology of Moscow City Health Department
Russian Federation
Russian Federation
Z. A. Nevozinskaya
Moscow Scientific and Practical Center of Dermatology, Venereology and Cosmetology of Moscow City Health Department
Russian Federation
PhD in medicine
Russian Federation
PhD in medicine
I. M. Korsunskaya
Center for Theoretical Problems of Physicochemical Pharmacology, Russian Academy of Sciences, Moscow
Russian Federation
Russian Federation
MD, Prof.
References
1. Van Krogh D, Lacey SD, Gross G, Barrasso R., Schneider A. European guidelines for anogenital warts. IPPP, 2002, 3: 29-37.
2. Aleksandrova YuN, Lyshchev AA, Safronnikova NR, et al. Papillomavirus infection in healthy women in St. Petersburg. Vopr. Onkol., 2000, 46(2): 175-179.
3. Kolomiets LA, Urazova LN. Genital papillomavirus infection and cervical cancer. Tomsk: NTL, 2002. 100 p.
4. Nyitray AG, Iannacone MR. The epidemiology of human papillomaviruses. Curr Probl Dermatol, 2014, 45(1): 75-91.
5. Krasnov V, Kulova A, Kulova E, et al. Rehabilitation in closed children’s institutions of frequently ill children with herpes infection activity markers. Vrach, 2007, 12: 68-70.
6. Prilepskaya VN, Kostava MN. Therapeutic potential of papillomavirus infection therapy. RMJ, 2009, 17 (1): 16-19.
7. Boyle P, Leon ME, Maisonneuve P, Autier P. Cancer Control In Women: Update 2003.Int J Gynaecol Obstet, 2003 Oct, 83(Suppl 1): 179–202.
8. Abramovskikh OS, Dolgushina VF, Telesheva LF, et al. Papillomavirus infection in the urogenital tract: epidemiological aspects (review). Ginekologiya, 2016, 18 (2): 34-39.
9. Clinical Effectiveness Group (British Association for Sexual Health and HIV). United Kingdom National guideline for the management of anogenital warts, 2007.
10. Soloviev AM, Perlamutrov YuN, Korsunskaya IМ. Immune system status in patients with recurrent infections in the urogenital tract. Immunologiya, Allergologiya, Infektologiya, 2013, 4: 49-56.
11. Laseev DI. The need for combined treatment of genital warts. In the collected papers: Actual problems of laser medicine, a collection of research papers. Edited by Petrischev NN. St. Petersburg, 2016: 71-72.
12. Kisina VI, Vorobiev PA. Patient management protocols. Sexually transmitted infections. M: Newdiamed, 2011.
13. Hersey P, Edwards A. Effect of Isoprinosine on natural killer cell activity of blood mononuclear cells in vitro and in vivo. Int J Immunopharmacol, 1984, 6: 315–320.
14. Diaz-Mitoma F, Turgonyl E, Kumar A et al. Clinical improvement in cronic fatigue syndrome is associated with enchanced natural killer cell-mediated cytotoxicity: the results of a pilot study with Isoprinosine. J Chron Fatig Syn, 2003, 11(2): 1–17.
15. Cillari E, Diell M, Lo Campo P et al. Protective effect of Isoprinosine in genetically susceptible BALB/c mice infected with Leishmania major. Immunology, 1991, 74: 25–30.
16. Mohanty KC, Scott CS. Immunotherapy of genital warts with inosine pranobex (Imunovir): preliminary stady. Genitourin Med, 1986, 62: 352–355.
17. Bagramova GE, Gureeva MA, Khlebnikova AN, Molochkov AV. Immunomodulatory therapy for papillomavirus infection. Klini cheskaya Dermatologiya i Venerologiya, 2011, 6: 47-50.
18. Kedrova AG, Podistov YuI, Kuznetsov VV, Kozachenko VL, Nikogosyan SО. The role of antiviral therapy in the combination treatment of patients with epithelial dysplasia and preinvasive cervical cancer. Ginekologiya, 2005, 7: 170-173.
19. Kedrova AG, Levakov SA, Chelnokova NN. Optimization of drug therapy for initial damage to the cervical epithelium associated with the human papillomavirus. Consilium Medicum, 2014, 16(6): 88-92.
20. Eliseeva MYu, Mynbayev OA. Adjuvant immunotherapy of HPV-associated lesions found in the areas of the mucous membranes and skin of the urogenital and perianal region. Ginekologiya, 2009, 11 (5): 22-33.
Review
For citations:
Melnichenko OO, Babaev OR, Shakhzadov VV, Nevozinskaya ZA, Korsunskaya IM. Papillomavirus infection. How to avoid relaps? Meditsinskiy sovet = Medical Council. 2018;(6):142-144. (In Russ.) https://doi.org/10.21518/2079-701X-2018-6-142-144
Views:
723
Email this article 